- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT00790569
Varenicline or Nicotine Patch and Nicotine Gum in Helping Smokers in a Methadone Treatment Program Stop Smoking
Varenicline Versus Nicotine Replacement for Methadone-Maintained Smokers
RATIONALE: Varenicline, the nicotine patch, and nicotine gum help people stop smoking. It is not yet known whether varenicline is more effective than the nicotine patch given together with nicotine gum in helping smokers quit smoking.
PURPOSE: This randomized clinical trial is studying varenicline to see how well it works compared with the nicotine patch given together with nicotine gum in helping smokers in a methadone treatment program stop smoking.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
OBJECTIVES:
Primary
- To determine whether varenicline, a nicotine receptor partial agonist, leads to a higher rate of smoking cessation than combination nicotine replacement therapy with nicotine patch prescription plus ad libitum nicotine gum delivery in methadone-maintained smokers.
Secondary
- To test the effects of the treatments on smoking urges, withdrawal symptoms, and reinforcing effects of smoking.
- To test the effects of the treatments on methadone treatment outcomes, including retention in methadone maintenance, methadone dose changes, and continued use of illicit drugs as measured by urine toxicologies.
OUTLINE: This is a multicenter study. Patients are stratified based on gender and level of nicotine dependence. Patients are randomized to 1 of 3 intervention arms.
At baseline, all patients receive a minimal behavioral intervention using a 3-minute, simple smoking cessation counseling strategy, a self-help manual, and a telephone quit-line number.
- Arm I (varenicline): Patients receive oral varenicline once daily on days 1-3 and twice daily thereafter for a total of 6 months or when a comfortable level of smoking abstinence is reached.
- Arm II (placebo): Patients receive oral varenicline placebo once daily on days 1-3 and twice daily thereafter for a total of 6 months or when a comfortable level of smoking abstinence is reached.
- Arm III (nicotine patch/gum): Patients receive a nicotine patch, with doses tapering over time for a total of 26 weeks. Patients also receive nicotine gum to quell breakthrough urges. Patients may stop treatment when a comfortable level of smoking abstinence is reached.
Patients complete a brief interview over 10-15 minutes at 2 weeks and monthly during months 1-5. They complete a longer interview over 45 minutes at months 6 and 12 and provide breath samples (for carbon monoxide monitoring) and urine samples (for cotinine testing).
NOTE: Smoking cessation may prevent certain smoking-related illnesses, including cancer.
PROJECTED ACCRUAL: A total of 602 patients (258 receiving varenicline, 258 receiving nicotine replacement therapy, and 86 receiving placebo) will be accrued for this study.
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
Rhode Island
-
Providence, Rhode Island, Estados Unidos, 02903
- Rhode Island Hospital Comprehensive Cancer Center
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
INCLUSION CRITERIA
- Current and regular cigarette smokers (over 10 cigarettes/day for the past 3 months)
Interested in quitting smoking
- Willing to set a quit date 7 days after baseline assessment
Participating in 1 of 5 methadone maintenance treatment programs across Rhode Island at any of the following institutions:
- Codac, Inc. (with two independent sites)
- Addiction Recovery Institute
- Center for Treatment and Recovery
- Discovery House
- Has received methadone for at least the past month
EXCLUSION CRITERIA
- Pregnant or nursing (Must have negative pregnancy test)
- Non-English speaking
- No personal telephone or does not live close to a relative or neighbor with a telephone
- Unwilling to make their methadone dose and methadone maintenance treatment program urine toxicologies available for review
- Unvailable for this study for the next 12 months
- Suffering from any unstable medical condition which would preclude the use of the nicotine patch (e.g., unstable angina or uncontrolled hypertension)
- Active skin condition (e.g., psoriasis)
- History of skin allergy
- History of a suicide attempt
- Working as pilots, drivers, or operators of heavy machinery
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- No concurrent insulin or blood thinners
- No concurrent smokeless tobacco, nicotine replacement therapy, or other smoking cessation treatment
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Prevenção
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Triplo
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Arm I
Patients receive oral varenicline once daily on days 1-3 and twice daily thereafter for a total of 6 months or when a comfortable level of smoking abstinence is reached.
|
Given orally
|
|
Comparador de Placebo: Arm II
Patients receive oral varenicline placebo once daily on days 1-3 and twice daily thereafter for a total of 6 months or when a comfortable level of smoking abstinence is reached.
|
Dado oralmente
|
|
Comparador Ativo: Arm III
Patients receive a nicotine patch, with doses tapering over time for a total of 26 weeks.
Patients also receive nicotine gum to quell breakthrough urges.
Patients may stop treatment when a comfortable level of smoking abstinence is reached.
|
Given transdermally and orally
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Self- Reported 7-day Abstinence
Prazo: 6 Months
|
Number of participants with self-reported, 7-day abstinence at 6-months
|
6 Months
|
|
Carbon Monoxide (CO)-Confirmed 7-day Abstinence
Prazo: 6-Months
|
Number of participants reporting 7-day abstinence at 6-months, confirmed with CO measurement.
|
6-Months
|
|
Rates of Smoking Cessation Continuous From First Quit Day to 6 Months
Prazo: 6-Months
|
Number of participants who self-reported continuous abstinence from their initial quit day (study day 14) to 6 Months
|
6-Months
|
|
Self-reported 7-day Abstinence
Prazo: 12 Months
|
Number of participants with self-reported 7-day abstinence at 12-months
|
12 Months
|
|
CO-confirmed 7-day Abstinence
Prazo: 12 Months
|
Number of participants reporting 7-day abstinence at 12-months, confirmed with CO measurement.
|
12 Months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in Smoking Urges
Prazo: 6 months
|
Smoking urges was measured on a 0 (not at all) - 100 (strongest feeling possible) scale.
Higher values represent greater urge to smoke.
Change in smoking urges was calculated as Follow-up score (6 month) - Baseline Score.
|
6 months
|
|
Withdrawal Symptoms
Prazo: 6 months
|
Withdrawal Symptoms were measured using a modified version of the Minnesota Behavior Rating Scale.
The scale asked subjects to rate their smoking withdrawal symptoms over the previous 24 hours on a scale from 0 (none) to 4 (severe).
Higher values indicate more severe withdrawal symptoms.
Change in withdrawal symptoms was calculated as Follow-up score (6 month) - Baseline Score.
|
6 months
|
|
Retention in Methadone Maintenance
Prazo: 12 months
|
12 months
|
|
|
Methadone Dose Changes
Prazo: 12 months
|
12 months
|
|
|
Use of Illicit Drugs as Measured by Urine Toxicologies
Prazo: 12 months
|
12 months
|
|
|
Reinforcing Effects of Smoking
Prazo: 6 months
|
Reinforcing effects of smoking was measured using the modified version of the Cigarette Evaluation Questionnaire.
Participants were asked to indicate on a 12-item scale how smoking made them feel in the prior 30 days on a scale from 1 (Not at all) to 7 (Extremely).
Higher values indicated that smoking was a more positive experience for 10 of 12 items.
Two items were reverse coded.
Change in reinforcing effects of smoking was calculated as Follow-up score (6 month) - Baseline Score.
|
6 months
|
|
Change in Cigarettes Per Day
Prazo: 6-Months
|
Change in mean cigarettes per day
|
6-Months
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Cadeira de estudo: Michael Stein, MD, Butler Hospital
Publicações e links úteis
Publicações Gerais
- Stein MD, Caviness CM, Kurth ME, Audet D, Olson J, Anderson BJ. Varenicline for smoking cessation among methadone-maintained smokers: a randomized clinical trial. Drug Alcohol Depend. 2013 Dec 1;133(2):486-93. doi: 10.1016/j.drugalcdep.2013.07.005. Epub 2013 Aug 14.
- de Dios MA, Anderson BJ, Caviness CM, Stein M. Intimate partner violence among individuals in methadone maintenance treatment. Subst Abus. 2014;35(2):190-3. doi: 10.1080/08897077.2013.835764.
- Caviness CM, Bird JL, Anderson BJ, Abrantes AM, Stein MD. Minimum recommended physical activity, and perceived barriers and benefits of exercise in methadone maintained persons. J Subst Abuse Treat. 2013 Apr;44(4):457-62. doi: 10.1016/j.jsat.2012.10.002. Epub 2012 Nov 28.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
- câncer de pulmão de células não pequenas
- câncer de esôfago
- Câncer de bexiga
- câncer de intestino
- câncer de pâncreas
- carcinoma de células renais
- câncer de pulmão de pequenas células
- câncer cervical
- câncer de orofaringe
- câncer de laringe
- câncer de hipofaringe
- câncer primário de fígado adulto
- câncer de lábio e cavidade oral
- câncer de nasofaringe
- câncer de seios paranasais e cavidade nasal
- Leucemia Mielóide Aguda do Adulto
- transtorno do uso do tabaco
Termos MeSH relevantes adicionais
- Transtornos Mentais, Desordem Mental
- Distúrbios induzidos quimicamente
- Doenças do aparelho digestivo
- Transtornos Relacionados a Substâncias
- Doenças Respiratórias
- Neoplasias
- Doenças pulmonares
- Neoplasias Urológicas
- Neoplasias urogenitais
- Neoplasias por local
- Doenças Urológicas
- Doenças da Bexiga Urinária
- Neoplasias uterinas
- Neoplasias Genitais Femininas
- Doenças do colo do útero
- Doenças uterinas
- Doenças do Sistema Endócrino
- Neoplasias gastrointestinais
- Neoplasias do Aparelho Digestivo
- Doenças Gastrointestinais
- Doenças do Estômago
- Neoplasias das Glândulas Endócrinas
- Doenças do Fígado
- Neoplasias do Trato Respiratório
- Neoplasias Torácicas
- Neoplasias de Cabeça e Pescoço
- Doenças Esofágicas
- Doenças pancreáticas
- Neoplasias do colo uterino
- Neoplasias do Estômago
- Neoplasias Pulmonares
- Transtorno do Uso de Tabaco
- Neoplasias da Bexiga Urinária
- Neoplasias Pancreáticas
- Neoplasias Hepáticas
- Neoplasias Esofágicas
- Efeitos Fisiológicos das Drogas
- Agentes Neurotransmissores
- Mecanismos Moleculares de Ação Farmacológica
- Agentes Autônomos
- Agentes do Sistema Nervoso Periférico
- Agentes colinérgicos
- Estimulantes ganglionares
- Agonistas Nicotínicos
- Agonistas colinérgicos
- Nicotina
- Vareniclina
Outros números de identificação do estudo
- CDR0000616663
- R01CA129226 (Concessão/Contrato do NIH dos EUA)
- BUTLER-0807-004
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .